TWIST it but don't spin it

Blood

Volumn 122, Issue 4, 2013, Pages 470-471

  Apperley, Jane F ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DNA; IMATINIB; INTERFERON; PROTEIN TYROSINE KINASE INHIBITOR; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; BLOOD; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; HUMAN; MINIMAL RESIDUAL DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; FEMALE; MALE; NOTE;

BENZAMIDES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; WITHHOLDING TREATMENT;

EID: 84886914746     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-506097     Document Type: Article

References (9)

1. Ross DM, Branford S, Seymour J.F., et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study. Blood. 2013; 122(4): 515-522.
2. Mahon FX, Réa D, Guilhot J., et al.; Intergroupe Français des Leucémies Myélöides Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11): 1029-1035.
3. Kantarjian HM, Shah NP, Cortes J.E., et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012; 119(5): 1123-1129.
4. Larson RA, Hochhaus A, Hughes T.P., et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012; 26(10): 2197-2203.
5. Ross DM, Branford S, Seymour J.F., et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010; 24(10): 1719-1724.
6. Cross NCP, White HE, Müller MC, Saglio G., Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26(10): 2172-2175.
7. Kuwabara A, Babb A, Ibrahim A., et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood. 2010; 116(6): 1014-1016.
8. Milojkovic D, Gerrard G, Paliompeis C., et al. The natural history of RTQ-PCR levels after the achievement of complete molecular remission (CMR): implications for 'stopping' studies [abstract]. Blood. 2011; 118(21): 278. Abstract 605.
9. Branford S, Ross D, Prime J., et al. Early molecular response and female sex strongly predict achievement of stable undetectable BCR-ABL1, a criterion for imatinib discontinuation in patients with CML [abstract]. Blood. 2012; 120(21). Abstract 165.